ATE222768T1 - Ctla-8 in kombination mit g-csf oder mit g-csf und il-6, und verwendung vom ctla-8 zur behandlung von infektionen - Google Patents
Ctla-8 in kombination mit g-csf oder mit g-csf und il-6, und verwendung vom ctla-8 zur behandlung von infektionenInfo
- Publication number
- ATE222768T1 ATE222768T1 AT96936385T AT96936385T ATE222768T1 AT E222768 T1 ATE222768 T1 AT E222768T1 AT 96936385 T AT96936385 T AT 96936385T AT 96936385 T AT96936385 T AT 96936385T AT E222768 T1 ATE222768 T1 AT E222768T1
- Authority
- AT
- Austria
- Prior art keywords
- ctla
- csf
- combination
- treat infections
- treat
- Prior art date
Links
- 102000013691 Interleukin-17 Human genes 0.000 title abstract 5
- 108050003558 Interleukin-17 Proteins 0.000 title abstract 5
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 title 2
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 title 2
- 108090001005 Interleukin-6 Proteins 0.000 title 1
- 208000015181 infectious disease Diseases 0.000 title 1
- 230000002159 abnormal effect Effects 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 239000003153 chemical reaction reagent Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000004962 physiological condition Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/193—Colony stimulating factors [CSF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/204—IL-6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Virology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US590995P | 1995-10-27 | 1995-10-27 | |
| US56974295A | 1995-12-08 | 1995-12-08 | |
| PCT/US1996/016315 WO1997015320A1 (en) | 1995-10-27 | 1996-10-23 | Novel uses of mammalian ctla-8 and related reagents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE222768T1 true ATE222768T1 (de) | 2002-09-15 |
Family
ID=26674918
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT96936385T ATE222768T1 (de) | 1995-10-27 | 1996-10-23 | Ctla-8 in kombination mit g-csf oder mit g-csf und il-6, und verwendung vom ctla-8 zur behandlung von infektionen |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP0862454B1 (de) |
| JP (2) | JP3253633B2 (de) |
| AT (1) | ATE222768T1 (de) |
| AU (1) | AU7439996A (de) |
| CA (1) | CA2235951C (de) |
| DE (1) | DE69623316T2 (de) |
| DK (1) | DK0862454T3 (de) |
| ES (1) | ES2181915T3 (de) |
| PT (1) | PT862454E (de) |
| WO (1) | WO1997015320A1 (de) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0417487D0 (en) | 2004-08-05 | 2004-09-08 | Novartis Ag | Organic compound |
| CA2646478A1 (en) | 2006-03-10 | 2007-09-20 | Zymogenetics, Inc. | Antibodies that bind both il-17a and il-17f and methods of using the same |
| US7790163B2 (en) | 2006-03-10 | 2010-09-07 | Zymogenetics, Inc. | Antibodies that bind both IL-17A and IL-17F and methods of using the same |
| CA2683145C (en) | 2007-04-27 | 2018-06-12 | Katherine E. Lewis | Antagonists to il-17a, il-17f, and il-23p19 and methods of use |
| KR101318549B1 (ko) | 2008-09-29 | 2013-10-16 | 로슈 글리카트 아게 | 인간 ｉｌ17 에 대한 항체 및 이의 용도 |
| US20100310502A1 (en) * | 2009-06-09 | 2010-12-09 | Anders Linden | Method of treating local infections in mammals |
| EP2834273B1 (de) | 2012-04-05 | 2018-08-22 | F.Hoffmann-La Roche Ag | Bispezifische antikörper gegen menschliches tweak und menschliches il17, und deren verwendungen |
| WO2014161570A1 (en) | 2013-04-03 | 2014-10-09 | Roche Glycart Ag | Antibodies against human il17 and uses thereof |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL96477A0 (en) * | 1989-12-01 | 1991-08-16 | Amgen Inc | Megakaryocyte production |
| DE69132051D1 (de) * | 1990-08-23 | 2000-04-20 | Chiron Corp | Verwendung des rekombinanten koloniestimulierenden faktors-1 |
| US6562333B1 (en) * | 1993-06-14 | 2003-05-13 | Schering Corporation | Purified mammalian CTLA-8 antigens and related reagents |
| EP0734265A1 (de) * | 1993-12-13 | 1996-10-02 | Novartis AG | IL - 6 Therapy |
-
1996
- 1996-10-23 PT PT96936385T patent/PT862454E/pt unknown
- 1996-10-23 CA CA002235951A patent/CA2235951C/en not_active Expired - Fee Related
- 1996-10-23 ES ES96936385T patent/ES2181915T3/es not_active Expired - Lifetime
- 1996-10-23 AT AT96936385T patent/ATE222768T1/de not_active IP Right Cessation
- 1996-10-23 DE DE69623316T patent/DE69623316T2/de not_active Expired - Fee Related
- 1996-10-23 JP JP51663197A patent/JP3253633B2/ja not_active Expired - Fee Related
- 1996-10-23 AU AU74399/96A patent/AU7439996A/en not_active Abandoned
- 1996-10-23 EP EP96936385A patent/EP0862454B1/de not_active Expired - Lifetime
- 1996-10-23 DK DK96936385T patent/DK0862454T3/da active
- 1996-10-23 WO PCT/US1996/016315 patent/WO1997015320A1/en not_active Ceased
-
2001
- 2001-09-11 JP JP2001275810A patent/JP2002145799A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| AU7439996A (en) | 1997-05-15 |
| HK1015692A1 (en) | 1999-10-22 |
| JPH10512293A (ja) | 1998-11-24 |
| CA2235951C (en) | 2003-04-01 |
| CA2235951A1 (en) | 1997-05-01 |
| DK0862454T3 (da) | 2002-12-30 |
| JP2002145799A (ja) | 2002-05-22 |
| DE69623316D1 (de) | 2002-10-02 |
| ES2181915T3 (es) | 2003-03-01 |
| PT862454E (pt) | 2002-11-29 |
| DE69623316T2 (de) | 2003-04-17 |
| EP0862454B1 (de) | 2002-08-28 |
| WO1997015320A1 (en) | 1997-05-01 |
| JP3253633B2 (ja) | 2002-02-04 |
| EP0862454A1 (de) | 1998-09-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL267381A (en) | A pharmaceutical preparation containing dextromethorphan and quinidine for the treatment of nervous disorders | |
| ATE184792T1 (de) | 2-bromomelatonin zur behandlung von schlafstörungen | |
| DE69333321D1 (de) | Verwendung eines Consensus-Interferons zur Reduzierung der Nebeneffekte in der Interferon Behandlung von viralen Hepatiten. | |
| IL134345A0 (en) | Methods for treatment of patients afflicted with multiple sclerosis using consensus interferon | |
| ES2160643T3 (es) | Composiciones que contienen g-csf y proteina de union al tnf. | |
| DE69424777D1 (de) | 3,4-diarylchromane zur behandlung von dermatitis | |
| DE69426471D1 (de) | Verwendung von Sulodexid und von Arzneimitteln, die dieses enthalten, zur Behandlung der diabetischen Nephropathie | |
| DK0680323T3 (da) | Synergistisk kombination med antagonistvirkning ved NK1- og Nk2-receptorer. | |
| ATE453402T1 (de) | Verwendung von serp-1 in kombination mit einem immunosuppressor zur behandlung von arthritis | |
| ATE222768T1 (de) | Ctla-8 in kombination mit g-csf oder mit g-csf und il-6, und verwendung vom ctla-8 zur behandlung von infektionen | |
| CA2156481A1 (en) | 5-ht2 receptor antagonist compositions useful in treating venous conditions | |
| ATE230609T1 (de) | Verfahren zur behandlung von entzündungen und zusammensetzungen dafür | |
| ATE236633T1 (de) | Topische verwendung von loperamid zur behandlung mikrobieller infektionen | |
| ATE306278T1 (de) | Behandlung von knochenleiden mit adrenomedullin | |
| ATE80998T1 (de) | Verwendung von nalmefen zur herstellung eines arzneimittels zur behandlung der schaedigung des zentralnervensystems. | |
| DE69330809D1 (de) | Therapeutisches Agens für Neutropenie | |
| DE69635282D1 (de) | Behandlung der exzessiven aggressivität mit olanzapine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 0862454 Country of ref document: EP |
|
| REN | Ceased due to non-payment of the annual fee |